Ono Pharmaceutical (OTCMKTS:OPHLY – Get Free Report) is expected to post its resultson Friday, July 31st. Analysts expect the company to post earnings of $0.0716 per share and revenue of $685.0340 million for the quarter.
Ono Pharmaceutical Price Performance
OTCMKTS OPHLY opened at $4.98 on Thursday. Ono Pharmaceutical has a 1 year low of $3.55 and a 1 year high of $5.75. The business’s 50-day moving average is $4.83 and its 200 day moving average is $5.01.
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.
See Also
- Five stocks we like better than Ono Pharmaceutical
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
